BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27272793)

  • 1. Histone Deacetylase-1-mediated Suppression of FAS in Chemoresistant Ovarian Cancer Cells.
    Cacan E
    Anticancer Res; 2016 Jun; 36(6):2819-26. PubMed ID: 27272793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.
    Ali MW; Cacan E; Liu Y; Pierce JY; Creasman WT; Murph MM; Govindarajan R; Eblen ST; Greer SF; Hooks SB
    PLoS One; 2013; 8(3):e60185. PubMed ID: 23533674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells.
    Cacan E
    Cell Biol Int; 2017 Mar; 41(3):328-339. PubMed ID: 28074529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells.
    Cacan E
    J Chemother; 2017 Jun; 29(3):173-178. PubMed ID: 28102109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.
    Cacan E; Ali MW; Boyd NH; Hooks SB; Greer SF
    PLoS One; 2014; 9(1):e87455. PubMed ID: 24475290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X; Fraser M; Qiu Q; Tsang BK
    Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
    Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
    Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
    Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
    Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
    Aghdassi A; Sendler M; Guenther A; Mayerle J; Behn CO; Heidecke CD; Friess H; Büchler M; Evert M; Lerch MM; Weiss FU
    Gut; 2012 Mar; 61(3):439-48. PubMed ID: 22147512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
    Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
    Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line.
    Viscarra T; Buchegger K; Jofre I; Riquelme I; Zanella L; Abanto M; Parker AC; Piccolo SR; Roa JC; Ili C; Brebi P
    Biol Res; 2019 Mar; 52(1):13. PubMed ID: 30894224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
    Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
    Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
    Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
    Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
    Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation-induced modulation of immunogenic genes in tumor cells is regulated by both histone deacetylases and DNA methyltransferases.
    Cacan E; Greer SF; Garnett-Benson C
    Int J Oncol; 2015 Dec; 47(6):2264-75. PubMed ID: 26458736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.